# Official Journal C 8/2011

| | ISSN 1725-2423
  doi:10.3000/17252423.C_2011.008.eng |
| --- | --- |
| Official Journal
  of the European Union | C 8 |
| | |
| English edition | Information and Notices | Volume 5413 January 2011 |

ISSN 1725-2423

doi:10.3000/17252423.C_2011.008.eng

Official Journal

of the European Union

C 8

English edition

Information and Notices

Volume 5413 January 2011

---

| Notice No | Contents | page |
| --- | --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2011/C 008/01 | Non-opposition to a notified concentration (Case COMP/M.5964 — TPV/Philips Branded Monitors and Colour TVS) (
  1
  ) | 1 |
| 2011/C 008/02 | Non-opposition to a notified concentration (Case COMP/M.6052 — London & Continental Railways/Lend Lease Europe/Stratford City Business District) (
  1
  ) | 1 |
| 2011/C 008/03 | Non-opposition to a notified concentration (Case COMP/M.5908 — Honeywell/Sperian) (
  1
  ) | 2 |
| 2011/C 008/04 | Communication from the Commission upon full use of the abatimento quota for 2010 (maize, Portugal) | 2 |

Notice No

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2011/C 008/01

Non-opposition to a notified concentration (Case COMP/M.5964 — TPV/Philips Branded Monitors and Colour TVS) (
  1
  )

1

1

2011/C 008/02

Non-opposition to a notified concentration (Case COMP/M.6052 — London & Continental Railways/Lend Lease Europe/Stratford City Business District) (
  1
  )

1

1

2011/C 008/03

Non-opposition to a notified concentration (Case COMP/M.5908 — Honeywell/Sperian) (
  1
  )

1

2

2011/C 008/04

Communication from the Commission upon full use of the abatimento quota for 2010 (maize, Portugal)

2

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2011/C 008/05 | Euro exchange rates | 3 |
| | NOTICES FROM MEMBER STATES |
| 2011/C 008/06 | Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 1857/2006 on the application of Articles 87 and 88 of the EC Treaty to State aid to small and medium-sized enterprises active in the production of agricultural products and amending Regulation (EC) No 70/2001 | 4 |
| | NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA |
| | Standing Committee of the EFTA States |
| 2011/C 008/07 | Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2010 | 7 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2011/C 008/05

Euro exchange rates

3

NOTICES FROM MEMBER STATES

2011/C 008/06

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 1857/2006 on the application of Articles 87 and 88 of the EC Treaty to State aid to small and medium-sized enterprises active in the production of agricultural products and amending Regulation (EC) No 70/2001

4

NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA

Standing Committee of the EFTA States

2011/C 008/07

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2010

7

| | V   Announcements |
| --- | --- |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY |
| | European Commission |
| 2011/C 008/08 | Initiation of proceedings (Case COMP/M.5907 — Votorantim/Fischer/JV) (
  1
  ) | 20 |

V   Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

2011/C 008/08

Initiation of proceedings (Case COMP/M.5907 — Votorantim/Fischer/JV) (
  1
  )

1

20

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

II Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 13.1.2011 | EN | Official Journal of the European Union | C 8/1 |
| --- | --- | --- | --- |

13.1.2011

EN

Official Journal of the European Union

C 8/1

---

Non-opposition to a notified concentration

(Case COMP/M.5964 — TPV/Philips Branded Monitors and Colour TVS)

(Text with EEA relevance)

2011/C 8/01

On 9 November 2010, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32010M5964. EUR-Lex is the on-line access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32010M5964. EUR-Lex is the on-line access to the European law.

---

| 13.1.2011 | EN | Official Journal of the European Union | C 8/1 |
| --- | --- | --- | --- |

13.1.2011

EN

Official Journal of the European Union

C 8/1

---

Non-opposition to a notified concentration

(Case COMP/M.6052 — London & Continental Railways/Lend Lease Europe/Stratford City Business District)

(Text with EEA relevance)

2011/C 8/02

On 7 January 2011, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32011M6052. EUR-Lex is the on-line access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32011M6052. EUR-Lex is the on-line access to the European law.

---

| 13.1.2011 | EN | Official Journal of the European Union | C 8/2 |
| --- | --- | --- | --- |

13.1.2011

EN

Official Journal of the European Union

C 8/2

---

Non-opposition to a notified concentration

(Case COMP/M.5908 — Honeywell/Sperian)

(Text with EEA relevance)

2011/C 8/03

On 4 August 2010, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32010M5908. EUR-Lex is the on-line access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32010M5908. EUR-Lex is the on-line access to the European law.

---

| 13.1.2011 | EN | Official Journal of the European Union | C 8/2 |
| --- | --- | --- | --- |

13.1.2011

EN

Official Journal of the European Union

C 8/2

---

Communication from the Commission upon full use of the ‘abatimento’ quota for 2010 (maize, Portugal)

2011/C 8/04

Commission Regulation (EU) No 1262/2010 (1) provides for the prolongation of the 2010 quota tenders for import from third countries, for release for free circulation in Portugal, of 500 000 tonnes of maize, until the quota is completely used and at the latest until 31 May 2011. As on Tuesday 14 December 2010 the quantity of the 2010 quota has been completely used, imports from 1 January 2011 shall count towards the 2011 quota.

---

(1)  OJ L 343, 29.12.2010, p. 76.

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 13.1.2011 | EN | Official Journal of the European Union | C 8/3 |
| --- | --- | --- | --- |

13.1.2011

EN

Official Journal of the European Union

C 8/3

---

Euro exchange rates (1)

12 January 2011

2011/C 8/05

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,2973 |
| JPY | Japanese yen | 108,17 |
| DKK | Danish krone | 7,4496 |
| GBP | Pound sterling | 0,83155 |
| SEK | Swedish krona | 8,8435 |
| CHF | Swiss franc | 1,2622 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 7,7060 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 24,390 |
| HUF | Hungarian forint | 275,57 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,7009 |
| PLN | Polish zloty | 3,8425 |
| RON | Romanian leu | 4,2525 |
| TRY | Turkish lira | 2,0377 |
| AUD | Australian dollar | 1,3098 |
| CAD | Canadian dollar | 1,2784 |
| HKD | Hong Kong dollar | 10,0858 |
| NZD | New Zealand dollar | 1,7113 |
| SGD | Singapore dollar | 1,6754 |
| KRW | South Korean won | 1 445,89 |
| ZAR | South African rand | 8,8815 |
| CNY | Chinese yuan renminbi | 8,5671 |
| HRK | Croatian kuna | 7,4015 |
| IDR | Indonesian rupiah | 11 715,84 |
| MYR | Malaysian ringgit | 3,9734 |
| PHP | Philippine peso | 57,017 |
| RUB | Russian rouble | 39,3615 |
| THB | Thai baht | 39,400 |
| BRL | Brazilian real | 2,1812 |
| MXN | Mexican peso | 15,6831 |
| INR | Indian rupee | 58,5050 |

Currency

Exchange rate

USD

US dollar

1,2973

JPY

Japanese yen

108,17

DKK

Danish krone

7,4496

GBP

Pound sterling

0,83155

SEK

Swedish krona

8,8435

CHF

Swiss franc

1,2622

ISK

Iceland króna

NOK

Norwegian krone

7,7060

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

24,390

HUF

Hungarian forint

275,57

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,7009

PLN

Polish zloty

3,8425

RON

Romanian leu

4,2525

TRY

Turkish lira

2,0377

AUD

Australian dollar

1,3098

CAD

Canadian dollar

1,2784

HKD

Hong Kong dollar

10,0858

NZD

New Zealand dollar

1,7113

SGD

Singapore dollar

1,6754

KRW

South Korean won

1 445,89

ZAR

South African rand

8,8815

CNY

Chinese yuan renminbi

8,5671

HRK

Croatian kuna

7,4015

IDR

Indonesian rupiah

11 715,84

MYR

Malaysian ringgit

3,9734

PHP

Philippine peso

57,017

RUB

Russian rouble

39,3615

THB

Thai baht

39,400

BRL

Brazilian real

2,1812

MXN

Mexican peso

15,6831

INR

Indian rupee

58,5050

---

(1)  Source: reference exchange rate published by the ECB.

---

NOTICES FROM MEMBER STATES

| 13.1.2011 | EN | Official Journal of the European Union | C 8/4 |
| --- | --- | --- | --- |

13.1.2011

EN

Official Journal of the European Union

C 8/4

---

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 1857/2006 on the application of Articles 87 and 88 of the EC Treaty to State aid to small and medium-sized enterprises active in the production of agricultural products and amending Regulation (EC) No 70/2001

2011/C 8/06

Aid No: XA 95/10

Member State: Spain

Region: Comunitat Valenciana

Title of aid scheme or name of company receiving an individual aid: Asociación de Usuarios de Casetas de Castellón

Legal basis: Resolución de 2010, de la Consellera de Agricultura, Pesca y Alimentación, por la que se concede una subvención nominativa a la Asociación de Usuarios de Casetas de Castellón.

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company: EUR 165 000 over the year 2010

Maximum aid intensity:

| — | 100 %, (Article 16 1(d) of Regulation (EC) No 1857/2006), |
| --- | --- |

—

100 %, (Article 16 1(d) of Regulation (EC) No 1857/2006),

| — | 50 % in less-favoured areas or 40 % in other regions (Article 2(a) and (b) of Regulation (EC) No 1857/2006). |
| --- | --- |

—

50 % in less-favoured areas or 40 % in other regions (Article 2(a) and (b) of Regulation (EC) No 1857/2006).

Date of implementation: From the date on which the identification number of the exemption request is published on the website of the Commission's Directorate-General for Agriculture and Rural Development

Duration of scheme or individual aid award: Throughout the year 2010

Objective of aid: Commission Regulation (EC) No 1857/2006 of 15 December 2006 on the application of Articles 87 and 88 of the EC Treaty on State aid to small and medium-sized enterprises active in the production of agricultural products and amending Regulation (EC) No 70/2001 (OJ L 358, 16.12.2006),

Article 16(1)(d)

Article 4(4)(a)

Sector(s) concerned: Owners of livestock holdings in the province of Castellón

Name and address of the granting authority:

| Conselleria de Agricultura, Pesca y Alimentación |
| --- |
| C/ Amadeo de Saboya, 2 |
| 46010 Valencia |
| ESPAÑA |

Conselleria de Agricultura, Pesca y Alimentación

C/ Amadeo de Saboya, 2

46010 Valencia

ESPAÑA

Website: http://www.agricultura.gva.es/web/c/document_library/get_file?uuid=d8311d4b-a36c-433f-b64e-1512cf00309f&groupId=16

Other information: —

Aid No: XA 178/10

Member State: Italy

Region: Marche

Title of aid scheme or name of company receiving an individual aid: aiuti per il pagamento dei premi assicurativi

Legal basis:

| — | Art. 2 comma 1 lettera a) della legge regionale 2 settembre 1997, n. 56 «Procedure relative agli aiuti compatibili con le disposizioni del Trattato di Roma con riguardo agli interventi straordinari nel settore agricolo» |
| --- | --- |

—

Art. 2 comma 1 lettera a) della legge regionale 2 settembre 1997, n. 56 «Procedure relative agli aiuti compatibili con le disposizioni del Trattato di Roma con riguardo agli interventi straordinari nel settore agricolo»

| — | DGR 2049 del 30 novembre 2009 ad oggetto: «Aiuti di Stato destinati ad ovviare e prevenire i danni arrecati dalle calamità naturali oppure da altri eventi» |
| --- | --- |

—

DGR 2049 del 30 novembre 2009 ad oggetto: «Aiuti di Stato destinati ad ovviare e prevenire i danni arrecati dalle calamità naturali oppure da altri eventi»

| — | DGR 1272 del 2 settembre 2010 ad oggetto «Modifica della DGR 2049 del 30 novembre 2009 Aiuti di stato destinati ad ovviare e prevenire i danni arrecati dalle calamità naturali oppure da altri eventi eccezionali [lr n. 56/97 art. 2 comma 1 lett. a)] — Indirizzi e criteri di erogazione». |
| --- | --- |

—

DGR 1272 del 2 settembre 2010 ad oggetto «Modifica della DGR 2049 del 30 novembre 2009 Aiuti di stato destinati ad ovviare e prevenire i danni arrecati dalle calamità naturali oppure da altri eventi eccezionali [lr n. 56/97 art. 2 comma 1 lett. a)] — Indirizzi e criteri di erogazione».

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company: The expenditure planned under this scheme will be determined annually on the basis of regional budget availability. Under the 2010 regional budget, EUR 308 065,93 is available. This amount constitutes the basis for expenditure over the coming years, subject to any decreases in the annual regional budget. Should it be necessary to exceed this basic amount of expenditure, a new aid request will submitted.

Beneficiaries:

Defence consortia and agricultural cooperatives and consortia authorised by the Marche Region within the meaning of Legislative Decree No 102/2004

Maximum aid intensity: Aid will be granted on the basis of the difference between the expenditure incurred by the Defence Organisations to pay for policies, as stipulated by Legislative Decree No 102/2004 as amended, and the maximum expenditure eligible for aid under the Annual Agricultural Insurance Plan, as stipulated in the opinion issued by the Region as specified in Article 13 of this Decree.

In accordance with Article 12 of Regulation (EC) No 1857/2006, gross aid intensity will not exceed:

| — | losses referred to in point (a) and against other losses caused by climatic events, and/or |
| --- | --- |

—

losses referred to in point (a) and against other losses caused by climatic events, and/or

| — | losses caused by animal or plant diseases or pest infestations. |
| --- | --- |

—

losses caused by animal or plant diseases or pest infestations.

The aid will not be limited to insurance provided by a single insurance company or group of companies, or be made subject to the condition that the insurance contract be taken out with a company established in Italy.

Date of implementation: From the date of publication of the identification number of the request for exemption on the website of the Commission’s Directorate-General for Agriculture and Rural Development

Duration of scheme or individual aid award: Under the scheme, aid may be granted until 31 December 2013 and for six months thereafter

Objective of aid: To encourage farmers to take out insurance against the risks of productions losses due to natural disasters, events assimilated to natural disasters, other disasters and losses caused by animal or plant diseases

Aid is granted on the basis of the provisions of Article 12 of Regulation (EC) No 1857/2006.

Sector(s) concerned: Agriculture — primary production

Name and address of the granting authority: Regione Marche — Giunta Regionale — Servizio Agricoltura, Forestazione e Pesca — PF Foreste e Irrigazione.

Website: http://www.agri.marche.it/Aree%20tematiche/Aiuti%20di%20stato/calamità2010.pdf

Other information: —

Il dirigente della pf foreste e irrigazione

Gabriella MASSACCESI

Aid No: XA 182/10

Member State: Federal Republic of Germany

Region: Niedersachsen

Title of aid scheme or name of company receiving an individual aid: Förderung nicht investiver Projekte im Bereich von landwirtschaftlichen Qualitätserzeugnissen aus ökologischem Landbau (VO (EG) Nr. 834/2007). Durchführung durch das Kompetenzzentrum Ökolandbau Niedersachsen (KÖN)

Legal basis: Landeshaushaltsordnung Niedersachsen

Erlass des Niedersächsischen Ministeriums für Ernährung, Landwirtschaft, Verbraucherschutz und Landesentwicklung (ML) vom 1. Juli 2010

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company: The overall annual cost of the projects is expected to be approximately EUR 600 000.

Maximum aid intensity: Up to 100 % of the eligible costs

Date of implementation: Implementation from 2010 — support commencing 1 January 2011

Duration of scheme or individual aid award: End of scheme and last payment December 2013

Objective of aid: Non-investment support for quality products in accordance with Regulation (EC) No 834/2007 (organic farming). Implementation is by the KÖN. Recipients of the aid are small and medium-sized enterprises which are engaged in the primary production of agricultural products from organic farming or small and medium-sized enterprises which are engaged in the primary production of agricultural products and which intend to convert their production to organic farming.

The projects cover:

General observation of market developments in organic farming (Article 14(2)(a) of Regulation (EC) No 1857/2006)

Introduction of quality assurance schemes (Article 14(2)(b) of Regulation (EC) No 1857/2006)

Education and training of farmers as well as consultancy services which relate to organic farming or to conversion to organic farming and which do not constitute a continuous or periodic activity (Article 15(2)(a) and (c) of Regulation (EC) No 1857/2006)

Forums to share knowledge between businesses, exhibitions and fairs (Article 15(2)(d) of Regulation (EC) No 1857/2006)

Vulgarisation of scientific knowledge and provision of factual information on quality systems (Article 15(2)(e) of Regulation (EC) No 1857/2006)

Publications (Article 15(2)(f) of Regulation (EC) No 1857/2006).

Sector(s) concerned: The projects are intended to be multi-sectoral and to take into account as far as possible all economic operators involved in primary agricultural production.

Name and address of the granting authority:

| Niedersächsisches Ministerium für Ernährung, Landwirtschaft, Verbraucherschutz und Landesentwicklung |
| --- |
| Calenberger Straße 2 |
| 30169 Hannover |
| Referat 107.2 |
| DEUTSCHLAND |

Niedersächsisches Ministerium für Ernährung, Landwirtschaft, Verbraucherschutz und Landesentwicklung

Calenberger Straße 2

30169 Hannover

Referat 107.2

DEUTSCHLAND

Website: http://www.ml.niedersachsen.de/live/live.php?navigation_id=26911&article_id=90411&_psmand=7

Other information: —

---

NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA

Standing Committee of the EFTA States

| 13.1.2011 | EN | Official Journal of the European Union | C 8/7 |
| --- | --- | --- | --- |

13.1.2011

EN

Official Journal of the European Union

C 8/7

---

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2010

2011/C 8/07

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2010, at their meeting on 1 October 2010:

| Annex I | List of new marketing authorisations |
| --- | --- |
| Annex II | List of renewed marketing authorisations |
| Annex III | List of extended marketing authorisations |
| Annex IV | List of withdrawn marketing authorisations |
| Annex V | List of suspended marketing authorisations |

Annex I

List of new marketing authorisations

Annex II

List of renewed marketing authorisations

Annex III

List of extended marketing authorisations

Annex IV

List of withdrawn marketing authorisations

Annex V

List of suspended marketing authorisations

---

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2010:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/06/367/001/NO-012/NO | Diacomit | Norway | 5.2.2010 |
| EU/1/08/476/005-006 | Adcirca | Liechtenstein | 28.2.2010 |
| EU/1/09/571/001/IS | Pandemic Influenza Vaccine H5N1 Baxter | Iceland | 27.1.2010 |
| EU/1/09/577/001/NO-004/NO | Foclivia | Norway | 18.2.2010 |
| EU/1/09/583/001/NO-072/NO | Irbesartan/Hydrochlorothiazide Teva | Norway | 18.1.2010 |
| EU/1/09/583/001-072 | Irbesartan/Hydrochlorothiazide Teva | Liechtenstein | 28.2.2010 |
| EU/1/09/584/001-018 | Sildenafil Teva | Liechtenstein | 28.2.2010 |
| EU/1/09/585/001/NO-018/NO | Rivastigmine 1A | Norway | 9.3.2010 |
| EU/1/09/585/001-018/IS | Rivastigmine 1A | Iceland | 2.3.2010 |
| EU/1/09/586/001/NO-010/NO | Oslif Breezhaler | Norway | 27.1.2010 |
| EU/1/09/586/001-010 | Oslif Breezhaler | Liechtenstein | 28.2.2010 |
| EU/1/09/587/001/NO-017/NO | Olanzapine Glenmark | Norway | 3.2.2010 |
| EU/1/09/587/001-017 | Olanzapine Glenmark | Liechtenstein | 28.2.2010 |
| EU/1/09/587/001-017/IS | Olanzapine Glenmark | Iceland | 25.1.2010 |
| EU/1/09/588/001/NO-012/NO | Olanzapine Glenmark Europe | Norway | 6.2.2010 |
| EU/1/09/588/001-012 | Olanzapine Glenmark Europe | Liechtenstein | 28.2.2010 |
| EU/1/09/588/001-012/IS | Olanzapine Glenmark Europe | Iceland | 25.1.2010 |
| EU/1/09/589/001/NO-018/NO | Rivastigmine Hexal | Norway | 9.3.2010 |
| EU/1/09/589/001-018 | Rivastigmine Hexal | Liechtenstein | 28.2.2010 |
| EU/1/09/589/001-018/IS | Rivastigmine Hexal | Iceland | 4.3.2010 |
| EU/1/09/590/001/NO-006/NO | Prevenar 13 | Norway | 18.1.2010 |
| EU/1/09/590/001-006 | Prevenar 13 | Liechtenstein | 28.2.2010 |
| EU/1/09/592/001/NO-005/NO | Olazax Disperzi | Norway | 4.2.2010 |
| EU/1/09/592/001-005 | Olazax Disperzi | Liechtenstein | 28.2.2010 |
| EU/1/09/592/001-005/IS | Olazax Disperzi | Iceland | 25.1.2010 |
| EU/1/09/593/001/NO-010/NO | Onbrez Breezhaler | Norway | 6.1.2010 |
| EU/1/09/593/001-010 | Onbrez Breezhaler | Liechtenstein | 28.2.2010 |
| EU/1/09/594/001/NO-010/NO | Hirobriz Breezhaler | Norway | 28.1.2010 |
| EU/1/09/594/001-010 | Hirobriz Breezhaler | Liechtenstein | 28.2.2010 |
| EU/1/09/595/001/NO-015/NO | Sildenafil Actavis | Norway | 13.1.2010 |
| EU/1/09/595/001-015/IS | Sildenafil Actavis | Iceland | 7.1.2010 |
| EU/1/09/596/001/NO-014/NO | Lamuvidine Teva Pharma BV | Norway | 11.1.2010 |
| EU/1/09/596/001-014 | Lamivudine Teva Pharma BV | Liechtenstein | 28.2.2010 |
| EU/1/09/596/001-014/IS | Lamivudine Teva Pharma BV | Iceland | 1.3.2010 |
| EU/1/09/597/001/NO-005/NO | Olazax | Norway | 4.2.2010 |
| EU/1/09/597/001-005/IS | Olazax | Iceland | 25.1.2010 |
| EU/1/09/598/001/NO-004/NO | Nevirapine Teva | Norway | 11.1.2010 |
| EU/1/09/598/001-004/IS | Nevirapine Teva | Iceland | 1.3.2010 |
| EU/1/09/599/001/NO-018/NO | Rivastigmine Sandoz | Norway | 9.3.2010 |
| EU/1/09/599/001-018/IS | Rivastigmine Sandoz | Iceland | 4.3.2010 |
| EU/1/09/600/001/IS | Zutectra | Iceland | 24.2.2010 |
| EU/1/09/600/001/NO | Zutectra | Norway | 11.1.2010 |
| EU/1/09/601/001 | Zenas | Liechtenstein | 28.2.2010 |
| EU/1/09/601/001/NO | Zenas | Norway | 4.2.2010 |
| EU/1/09/601/001/IS | Zenas | Iceland | 20.1.2010 |
| EU/1/09/602/001/NO-002/NO | Scintimun | Norway | 25.1.2010 |
| EU/1/09/602/001-002 | Scintimun | Liechtenstein | 28.2.2010 |
| EU/1/09/602/001-002/IS | Scintimun | Iceland | 21.1.2010 |
| EU/1/09/603/001/NO-012/NO | Sildenafil ratiopharm | Norway | 13.1.2010 |
| EU/1/09/603/001-012 | Sildenafil ratiopharm | Liechtenstein | 28.2.2010 |
| EU/1/09/603/001-012/IS | Sildenafil ratiopharm | Iceland | 18.1.2010 |
| EU/1/09/604/001/NO-010/NO | Leflunomide Winthrop | Norway | 4.2.2010 |
| EU/1/09/604/001-010 | Leflunomide Winthrop | Liechtenstein | 28.2.2010 |
| EU/1/09/604/001-010/IS | Leflunomide Winthrop | Iceland | 22.1.2010 |
| EU/1/09/605/001-012 | Temomedac | Liechtenstein | 28.2.2010 |
| EU/1/09/605/001-012/IS | Temomedac | Iceland | 24.2.2010 |
| EU/1/09/606/001/NO-012/NO | Temozolomide | Norway | 15.2.2010 |
| EU/1/09/606/001-012 | Temozolomide | Liechtenstein | 28.2.2010 |
| EU/1/09/606/001-012/IS | Temozolomide | Iceland | 16.2.2010 |
| EU/1/09/607/001/NO-014/NO | Silodyx | Norway | 9.2.2010 |
| EU/1/09/607/001-014 | Silodyx | Liechtenstein | 28.2.2010 |
| EU/1/09/607/001-014/IS | Silodyx | Iceland | 16.3.2010 |
| EU/1/09/608/001/NO-014/NO | Urorec | Norway | 9.2.2010 |
| EU/1/09/608/001-014 | Urorec | Liechtenstein | 28.2.2010 |
| EU/1/09/608/001-014/IS | Urorec | Iceland | 16.3.2010 |
| EU/1/09/609/001/NO-002/NO | Elonva | Norway | 11.3.2010 |
| EU/1/09/609/001-002 | Elonva | Liechtenstein | 28.2.2010 |
| EU/1/09/609/001-002/IS | Elonva | Iceland | 10.2.2010 |
| EU/1/09/610/001/NO-030/NO | Telmisartan Teva | Norway | 2.3.2010 |
| EU/1/09/610/001-030 | Telmisartan Teva | Liechtenstein | 28.2.2010 |
| EU/1/09/610/001-030/IS | Telmisartan Teva | Iceland | 16.3.2010 |
| EU/1/09/611/001/NO-002/NO | Docetaxel Teva | Norway | 26.2.2010 |
| EU/1/09/611/001-002 | Docetaxel Teva | Liechtenstein | 28.2.2010 |
| EU/1/09/611/001-002/IS | Docetaxel Teva | Iceland | 23.2.2010 |
| EU/1/10/612/001/NO-006/NO | Revolade | Norway | 25.3.2010 |
| EU/1/10/612/001-006 | Revolade | Liechtenstein | 30.4.2010 |
| EU/1/10/612/001-006/IS | Revolade | Iceland | 7.4.2010 |
| EU/1/10/613/001/NO-002/NO | ImmunoGam | Norway | 19.4.2010 |
| EU/1/10/613/001-002 | ImmunoGam | Liechtenstein | 30.4.2010 |
| EU/1/10/613/001-002/IS | ImmunoGam | Iceland | 28.4.2010 |
| EU/1/10/614/001 | Menveo | Liechtenstein | 30.4.2010 |
| EU/1/10/614/001/IS | Menveo | Iceland | 15.6.2010 |
| EU/1/10/614/001/NO | Menveo | Norway | 21.4.2010 |
| EU/1/10/615/001/NO-024/NO | Temozolomide Hospira | Norway | 24.3.2010 |
| EU/1/10/615/001-024 | Temozolomide Hospira | Liechtenstein | 30.4.2010 |
| EU/1/10/615/001-024/IS | Temozolomide Hospira | Iceland | 3.5.2010 |
| EU/1/10/616/001/NO-024/NO | Temozolomide Hexal | Norway | 26.4.2010 |
| EU/1/10/616/001-024 | Temozolomide Hexal | Liechtenstein | 30.4.2010 |
| EU/1/10/616/001-024/IS | Temozolomide Hexal | Iceland | 27.4.2010 |
| EU/1/10/617/001/NO-024/NO | Temozolomide Sandoz | Norway | 26.4.2010 |
| EU/1/10/617/001-024 | Temozolomide Sandoz | Liechtenstein | 30.4.2010 |
| EU/1/10/617/001-024/IS | Temozolomide Sandoz | Iceland | 27.4.2010 |
| EU/1/10/618/001-004 | Prolia | Liechtenstein | 30.6.2010 |
| EU/1/10/618/001-004/IS | Prolia | Iceland | 23.6.2010 |
| EU/1/10/619/001/NO-014/NO | DuoPlavin | Norway | 23.3.2010 |
| EU/1/10/619/001-014 | DuoPlavin | Liechtenstein | 30.4.2010 |
| EU/1/10/619/001-014/IS | DuoPlavin | Iceland | 21.4.2010 |
| EU/1/10/620/001/NO-016/NO | Ristfor | Norway | 3.6.2010 |
| EU/1/10/620/001-016 | Ristfor | Liechtenstein | 30.4.2010 |
| EU/1/10/620/001-016/IS | Ristfor | Iceland | 5.5.2010 |
| EU/1/10/621/001/NO-018/NO | Ristaben | Norway | 3.6.2010 |
| EU/1/10/621/001-018 | Ristaben | Liechtenstein | 30.4.2010 |
| EU/1/10/621/001-018/IS | Ristaben | Iceland | 5.5.2010 |
| EU/1/10/622/001/NO-002/NO | Tepadina | Norway | 25.3.2010 |
| EU/1/10/622/001-002/IS | Tepadina | Iceland | 21.4.2010 |
| EU/1/10/622/001-002 | Tepadina | Liechtenstein | 30.4.2010 |
| EU/1/10/623/001/NO-014/NO | DuoCover | Norway | 23.3.2010 |
| EU/1/10/623/001-014 | DuoCover | Liechtenstein | 30.4.2010 |
| EU/1/10/623/001-014/IS | DuoCover | Iceland | 21.4.2010 |
| EU/1/10/624/001 | Arepanrix | Liechtenstein | 30.4.2010 |
| EU/1/10/624/001/IS | Arepanrix | Iceland | 21.5.2010 |
| EU/1/10/625/001/NO-002/NO | Arzerra | Norway | 12.5.2010 |
| EU/1/10/625/001-002 | Arzerra | Liechtenstein | 30.4.2010 |
| EU/1/10/625/001-002/IS | Arzerra | Iceland | 17.5.2010 |
| EU/1/10/626/001/NO-004/NO | Ribavirin BioPartners | Norway | 22.4.2010 |
| EU/1/10/626/001-004/IS | Ribavirin BioPartners | Iceland | 17.5.2010 |
| EU/1/10/627/001/NO-003/NO | Raloxifene Teva | Norway | 31.5.2010 |
| EU/1/10/627/001-003 | Raloxifene Teva | Liechtenstein | 30.4.2010 |
| EU/1/10/627/001-003/IS | Raloxifene Teva | Iceland | 18.6.2010 |
| EU/1/10/628/001/NO-004/NO | Votrient | Norway | 28.6.2010 |
| EU/1/10/628/001-004 | Votrient | Liechtenstein | 30.6.2010 |
| EU/1/10/628/001-004/IS | Votrient | Iceland | 28.6.2010 |
| EU/1/10/629/001 | Humenza | Liechtenstein | 30.6.2010 |
| EU/1/10/629/001/IS | Humenza | Iceland | 28.6.2010 |
| EU/1/10/630/001/NO-002/NO | Docefrez | Norway | 7.6.2010 |
| EU/1/10/630/001-002 | Docefrez | Liechtenstein | 30.6.2010 |
| EU/1/10/630/001-002/IS | Docefrez | Iceland | 29.6.2010 |
| EU/1/10/631/001-009 | Nivestim | Liechtenstein | 30.6.2010 |
| EU/1/10/632/001-021 | Tolura | Liechtenstein | 30.6.2010 |
| EU/1/10/633/001/NO-002/NO | Topotecan Hospira | Norway | 22.6.2010 |
| EU/1/10/633/001-002 | Topotecan Hospira | Liechtenstein | 30.6.2010 |
| EU/1/10/634/001-004 | Ribaverin Three Rivers | Liechtenstein | 30.6.2010 |
| EU/1/10/634/001-004/IS | Ribavirin Three Rivers | Iceland | 28.6.2010 |
| EU/1/10/635/001-014 | Olanzapine Apotex | Liechtenstein | 30.6.2010 |
| EU/1/10/635/001-014/IS | Olanzapine Apotex | Iceland | 28.6.2010 |
| EU/2/08/085/001/NO | Easotic | Norway | 4.5.2010 |
| EU/2/08/090/001-008/IS | Loxicom | Iceland | 23.2.2010 |
| EU/2/09/096/001/NO-002/NO | Leucogen | Norway | 8.2.2010 |
| EU/2/09/101/001/NO-010/NO | Zolvix | Norway | 8.2.2010 |
| EU/2/09/101/001-010/IS | Zolvix | Iceland | 4.3.2010 |
| EU/2/09/102/001/NO-006/NO | Gripovac 3 | Norway | 21.4.2010 |
| EU/2/09/102/001-006 | Gripovac 3 | Liechtenstein | 28.2.2010 |
| EU/2/09/102/001-006/IS | Gripovac 3 | Iceland | 4.3.2010 |
| EU/2/09/103/001-006 | Respiporc FLU3 | Liechtenstein | 28.2.2010 |
| EU/2/09/103/001-006/IS | Respiporc FLU3 | Iceland | 4.3.2010 |
| EU/2/09/104/001/NO-002/NO | Zulvac 8 Ovis | Norway | 11.2.2010 |
| EU/2/09/104/001-002 | Zulvac 8 Ovis | Liechtenstein | 28.2.2010 |
| EU/2/09/104/001-002/IS | Zulvac 8 Ovis | Iceland | 28.1.2010 |
| EU/2/09/105/001/NO-002/NO | Zulvac 8 Bovis | Norway | 8.2.2010 |
| EU/2/09/105/001-002 | Zulvac 8 Bovis | Liechtenstein | 28.2.2010 |
| EU/2/09/105/001-002/IS | Zulvac 8 Bovis | Iceland | 27.1.2010 |

EU-Number

Product

Country

Date of authorisation

EU/1/06/367/001/NO-012/NO

Diacomit

Norway

5.2.2010

EU/1/08/476/005-006

Adcirca

Liechtenstein

28.2.2010

EU/1/09/571/001/IS

Pandemic Influenza Vaccine H5N1 Baxter

Iceland

27.1.2010

EU/1/09/577/001/NO-004/NO

Foclivia

Norway

18.2.2010

EU/1/09/583/001/NO-072/NO

Irbesartan/Hydrochlorothiazide Teva

Norway

18.1.2010

EU/1/09/583/001-072

Irbesartan/Hydrochlorothiazide Teva

Liechtenstein

28.2.2010

EU/1/09/584/001-018

Sildenafil Teva

Liechtenstein

28.2.2010

EU/1/09/585/001/NO-018/NO

Rivastigmine 1A

Norway

9.3.2010

EU/1/09/585/001-018/IS

Rivastigmine 1A

Iceland

2.3.2010

EU/1/09/586/001/NO-010/NO

Oslif Breezhaler

Norway

27.1.2010

EU/1/09/586/001-010

Oslif Breezhaler

Liechtenstein

28.2.2010

EU/1/09/587/001/NO-017/NO

Olanzapine Glenmark

Norway

3.2.2010

EU/1/09/587/001-017

Olanzapine Glenmark

Liechtenstein

28.2.2010

EU/1/09/587/001-017/IS

Olanzapine Glenmark

Iceland

25.1.2010

EU/1/09/588/001/NO-012/NO

Olanzapine Glenmark Europe

Norway

6.2.2010

EU/1/09/588/001-012

Olanzapine Glenmark Europe

Liechtenstein

28.2.2010

EU/1/09/588/001-012/IS

Olanzapine Glenmark Europe

Iceland

25.1.2010

EU/1/09/589/001/NO-018/NO

Rivastigmine Hexal

Norway

9.3.2010

EU/1/09/589/001-018

Rivastigmine Hexal

Liechtenstein

28.2.2010

EU/1/09/589/001-018/IS

Rivastigmine Hexal

Iceland

4.3.2010

EU/1/09/590/001/NO-006/NO

Prevenar 13

Norway

18.1.2010

EU/1/09/590/001-006

Prevenar 13

Liechtenstein

28.2.2010

EU/1/09/592/001/NO-005/NO

Olazax Disperzi

Norway

4.2.2010

EU/1/09/592/001-005

Olazax Disperzi

Liechtenstein

28.2.2010

EU/1/09/592/001-005/IS

Olazax Disperzi

Iceland

25.1.2010

EU/1/09/593/001/NO-010/NO

Onbrez Breezhaler

Norway

6.1.2010

EU/1/09/593/001-010

Onbrez Breezhaler

Liechtenstein

28.2.2010

EU/1/09/594/001/NO-010/NO

Hirobriz Breezhaler

Norway

28.1.2010

EU/1/09/594/001-010

Hirobriz Breezhaler

Liechtenstein

28.2.2010

EU/1/09/595/001/NO-015/NO

Sildenafil Actavis

Norway

13.1.2010

EU/1/09/595/001-015/IS

Sildenafil Actavis

Iceland

7.1.2010

EU/1/09/596/001/NO-014/NO

Lamuvidine Teva Pharma BV

Norway

11.1.2010

EU/1/09/596/001-014

Lamivudine Teva Pharma BV

Liechtenstein

28.2.2010

EU/1/09/596/001-014/IS

Lamivudine Teva Pharma BV

Iceland

1.3.2010

EU/1/09/597/001/NO-005/NO

Olazax

Norway

4.2.2010

EU/1/09/597/001-005/IS

Olazax

Iceland

25.1.2010

EU/1/09/598/001/NO-004/NO

Nevirapine Teva

Norway

11.1.2010

EU/1/09/598/001-004/IS

Nevirapine Teva

Iceland

1.3.2010

EU/1/09/599/001/NO-018/NO

Rivastigmine Sandoz

Norway

9.3.2010

EU/1/09/599/001-018/IS

Rivastigmine Sandoz

Iceland

4.3.2010

EU/1/09/600/001/IS

Zutectra

Iceland

24.2.2010

EU/1/09/600/001/NO

Zutectra

Norway

11.1.2010

EU/1/09/601/001

Zenas

Liechtenstein

28.2.2010

EU/1/09/601/001/NO

Zenas

Norway

4.2.2010

EU/1/09/601/001/IS

Zenas

Iceland

20.1.2010

EU/1/09/602/001/NO-002/NO

Scintimun

Norway

25.1.2010

EU/1/09/602/001-002

Scintimun

Liechtenstein

28.2.2010

EU/1/09/602/001-002/IS

Scintimun

Iceland

21.1.2010

EU/1/09/603/001/NO-012/NO

Sildenafil ratiopharm

Norway

13.1.2010

EU/1/09/603/001-012

Sildenafil ratiopharm

Liechtenstein

28.2.2010

EU/1/09/603/001-012/IS

Sildenafil ratiopharm

Iceland

18.1.2010

EU/1/09/604/001/NO-010/NO

Leflunomide Winthrop

Norway

4.2.2010

EU/1/09/604/001-010

Leflunomide Winthrop

Liechtenstein

28.2.2010

EU/1/09/604/001-010/IS

Leflunomide Winthrop

Iceland

22.1.2010

EU/1/09/605/001-012

Temomedac

Liechtenstein

28.2.2010

EU/1/09/605/001-012/IS

Temomedac

Iceland

24.2.2010

EU/1/09/606/001/NO-012/NO

Temozolomide

Norway

15.2.2010

EU/1/09/606/001-012

Temozolomide

Liechtenstein

28.2.2010

EU/1/09/606/001-012/IS

Temozolomide

Iceland

16.2.2010

EU/1/09/607/001/NO-014/NO

Silodyx

Norway

9.2.2010

EU/1/09/607/001-014

Silodyx

Liechtenstein

28.2.2010

EU/1/09/607/001-014/IS

Silodyx

Iceland

16.3.2010

EU/1/09/608/001/NO-014/NO

Urorec

Norway

9.2.2010

EU/1/09/608/001-014

Urorec

Liechtenstein

28.2.2010

EU/1/09/608/001-014/IS

Urorec

Iceland

16.3.2010

EU/1/09/609/001/NO-002/NO

Elonva

Norway

11.3.2010

EU/1/09/609/001-002

Elonva

Liechtenstein

28.2.2010

EU/1/09/609/001-002/IS

Elonva

Iceland

10.2.2010

EU/1/09/610/001/NO-030/NO

Telmisartan Teva

Norway

2.3.2010

EU/1/09/610/001-030

Telmisartan Teva

Liechtenstein

28.2.2010

EU/1/09/610/001-030/IS

Telmisartan Teva

Iceland

16.3.2010

EU/1/09/611/001/NO-002/NO

Docetaxel Teva

Norway

26.2.2010

EU/1/09/611/001-002

Docetaxel Teva

Liechtenstein

28.2.2010

EU/1/09/611/001-002/IS

Docetaxel Teva

Iceland

23.2.2010

EU/1/10/612/001/NO-006/NO

Revolade

Norway

25.3.2010

EU/1/10/612/001-006

Revolade

Liechtenstein

30.4.2010

EU/1/10/612/001-006/IS

Revolade

Iceland

7.4.2010

EU/1/10/613/001/NO-002/NO

ImmunoGam

Norway

19.4.2010

EU/1/10/613/001-002

ImmunoGam

Liechtenstein

30.4.2010

EU/1/10/613/001-002/IS

ImmunoGam

Iceland

28.4.2010

EU/1/10/614/001

Menveo

Liechtenstein

30.4.2010

EU/1/10/614/001/IS

Menveo

Iceland

15.6.2010

EU/1/10/614/001/NO

Menveo

Norway

21.4.2010

EU/1/10/615/001/NO-024/NO

Temozolomide Hospira

Norway

24.3.2010

EU/1/10/615/001-024

Temozolomide Hospira

Liechtenstein

30.4.2010

EU/1/10/615/001-024/IS

Temozolomide Hospira

Iceland

3.5.2010

EU/1/10/616/001/NO-024/NO

Temozolomide Hexal

Norway

26.4.2010

EU/1/10/616/001-024

Temozolomide Hexal

Liechtenstein

30.4.2010

EU/1/10/616/001-024/IS

Temozolomide Hexal

Iceland

27.4.2010

EU/1/10/617/001/NO-024/NO

Temozolomide Sandoz

Norway

26.4.2010

EU/1/10/617/001-024

Temozolomide Sandoz

Liechtenstein

30.4.2010

EU/1/10/617/001-024/IS

Temozolomide Sandoz

Iceland

27.4.2010

EU/1/10/618/001-004

Prolia

Liechtenstein

30.6.2010

EU/1/10/618/001-004/IS

Prolia

Iceland

23.6.2010

EU/1/10/619/001/NO-014/NO

DuoPlavin

Norway

23.3.2010

EU/1/10/619/001-014

DuoPlavin

Liechtenstein

30.4.2010

EU/1/10/619/001-014/IS

DuoPlavin

Iceland

21.4.2010

EU/1/10/620/001/NO-016/NO

Ristfor

Norway

3.6.2010

EU/1/10/620/001-016

Ristfor

Liechtenstein

30.4.2010

EU/1/10/620/001-016/IS

Ristfor

Iceland

5.5.2010

EU/1/10/621/001/NO-018/NO

Ristaben

Norway

3.6.2010

EU/1/10/621/001-018

Ristaben

Liechtenstein

30.4.2010

EU/1/10/621/001-018/IS

Ristaben

Iceland

5.5.2010

EU/1/10/622/001/NO-002/NO

Tepadina

Norway

25.3.2010

EU/1/10/622/001-002/IS

Tepadina

Iceland

21.4.2010

EU/1/10/622/001-002

Tepadina

Liechtenstein

30.4.2010

EU/1/10/623/001/NO-014/NO

DuoCover

Norway

23.3.2010

EU/1/10/623/001-014

DuoCover

Liechtenstein

30.4.2010

EU/1/10/623/001-014/IS

DuoCover

Iceland

21.4.2010

EU/1/10/624/001

Arepanrix

Liechtenstein

30.4.2010

EU/1/10/624/001/IS

Arepanrix

Iceland

21.5.2010

EU/1/10/625/001/NO-002/NO

Arzerra

Norway

12.5.2010

EU/1/10/625/001-002

Arzerra

Liechtenstein

30.4.2010

EU/1/10/625/001-002/IS

Arzerra

Iceland

17.5.2010

EU/1/10/626/001/NO-004/NO

Ribavirin BioPartners

Norway

22.4.2010

EU/1/10/626/001-004/IS

Ribavirin BioPartners

Iceland

17.5.2010

EU/1/10/627/001/NO-003/NO

Raloxifene Teva

Norway

31.5.2010

EU/1/10/627/001-003

Raloxifene Teva

Liechtenstein

30.4.2010

EU/1/10/627/001-003/IS

Raloxifene Teva

Iceland

18.6.2010

EU/1/10/628/001/NO-004/NO

Votrient

Norway

28.6.2010

EU/1/10/628/001-004

Votrient

Liechtenstein

30.6.2010

EU/1/10/628/001-004/IS

Votrient

Iceland

28.6.2010

EU/1/10/629/001

Humenza

Liechtenstein

30.6.2010

EU/1/10/629/001/IS

Humenza

Iceland

28.6.2010

EU/1/10/630/001/NO-002/NO

Docefrez

Norway

7.6.2010

EU/1/10/630/001-002

Docefrez

Liechtenstein

30.6.2010

EU/1/10/630/001-002/IS

Docefrez

Iceland

29.6.2010

EU/1/10/631/001-009

Nivestim

Liechtenstein

30.6.2010

EU/1/10/632/001-021

Tolura

Liechtenstein

30.6.2010

EU/1/10/633/001/NO-002/NO

Topotecan Hospira

Norway

22.6.2010

EU/1/10/633/001-002

Topotecan Hospira

Liechtenstein

30.6.2010

EU/1/10/634/001-004

Ribaverin Three Rivers

Liechtenstein

30.6.2010

EU/1/10/634/001-004/IS

Ribavirin Three Rivers

Iceland

28.6.2010

EU/1/10/635/001-014

Olanzapine Apotex

Liechtenstein

30.6.2010

EU/1/10/635/001-014/IS

Olanzapine Apotex

Iceland

28.6.2010

EU/2/08/085/001/NO

Easotic

Norway

4.5.2010

EU/2/08/090/001-008/IS

Loxicom

Iceland

23.2.2010

EU/2/09/096/001/NO-002/NO

Leucogen

Norway

8.2.2010

EU/2/09/101/001/NO-010/NO

Zolvix

Norway

8.2.2010

EU/2/09/101/001-010/IS

Zolvix

Iceland

4.3.2010

EU/2/09/102/001/NO-006/NO

Gripovac 3

Norway

21.4.2010

EU/2/09/102/001-006

Gripovac 3

Liechtenstein

28.2.2010

EU/2/09/102/001-006/IS

Gripovac 3

Iceland

4.3.2010

EU/2/09/103/001-006

Respiporc FLU3

Liechtenstein

28.2.2010

EU/2/09/103/001-006/IS

Respiporc FLU3

Iceland

4.3.2010

EU/2/09/104/001/NO-002/NO

Zulvac 8 Ovis

Norway

11.2.2010

EU/2/09/104/001-002

Zulvac 8 Ovis

Liechtenstein

28.2.2010

EU/2/09/104/001-002/IS

Zulvac 8 Ovis

Iceland

28.1.2010

EU/2/09/105/001/NO-002/NO

Zulvac 8 Bovis

Norway

8.2.2010

EU/2/09/105/001-002

Zulvac 8 Bovis

Liechtenstein

28.2.2010

EU/2/09/105/001-002/IS

Zulvac 8 Bovis

Iceland

27.1.2010

---

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2010:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/00/129/001-003 | Azopt | Liechtenstein | 28.2.2010 |
| EU/1/00/129/001-003/IS | Azopt | Iceland | 16.3.2010 |
| EU/1/00/130/001/NO-002/NO | Orgalutran | Norway | 8.6.2010 |
| EU/1/00/130/001-002 | Orgalutran | Liechtenstein | 30.6.2010 |
| EU/1/00/130/001-002/IS | Orgalutran | Iceland | 25.6.2010 |
| EU/1/00/131/001/NO-005/NO | PegIntron | Norway | 26.5.2010 |
| EU/1/00/131/001-050 | PegIntron | Liechtenstein | 30.6.2010 |
| EU/1/00/131/001-050/IS | PegIntron | Iceland | 24.6.2010 |
| EU/1/00/132/001/NO-050/NO | ViraferonPeg | Norway | 26.5.2010 |
| EU/1/00/132/001-050 | ViraferonPeg | Liechtenstein | 30.6.2010 |
| EU/1/00/132/001-050/IS | ViraferonPeg | Iceland | 25.6.2010 |
| EU/1/00/133/001/NO-032/NO | Optisulin | Norway | 25.5.2010 |
| EU/1/00/133/001-032 | Optisulin | Liechtenstein | 30.6.2010 |
| EU/1/00/133/001-032/IS | Optisulin | Iceland | 25.6.2010 |
| EU/1/00/134/001/NO-037/NO | Lantus | Norway | 25.5.2010 |
| EU/1/00/134/001-037 | Lantus | Liechtenstein | 30.6.2010 |
| EU/1/00/134/001-037/IS | Lantus | Iceland | 25.6.2010 |
| EU/1/00/137/002/NO-018/NO | Avandia | Norway | 7.6.2010 |
| EU/1/00/137/002-012/IS | Avandia | Iceland | 18.6.2010 |
| EU/1/00/137/002-018 | Avandia | Liechtenstein | 30.6.2010 |
| EU/1/00/140/001 | Visudyne | Liechtenstein | 30.6.2010 |
| EU/1/00/140/001/IS | Visudyne | Iceland | 23.6.2010 |
| EU/1/04/272/001/NO-002/NO | PhotoBarr | Norway | 17.2.2010 |
| EU/1/04/294/001-028 | Emselex | Liechtenstein | 28.2.2010 |
| EU/1/04/298/001/NO-003/NO | Kivexa | Norway | 19.1.2010 |
| EU/1/04/298/001-003 | Kivexa | Liechtenstein | 28.2.2010 |
| EU/1/04/299/001/NO-003/NO | Fendrix | Norway | 3.2.2010 |
| EU/1/04/299/001-003 | Fendrix | Liechtenstein | 28.2.2010 |
| EU/1/04/299/001-003/IS | Fendrix | Iceland | 7.1.2010 |
| EU/1/04/300/001/NO-002/NO | Avastin | Norway | 26.1.2010 |
| EU/1/04/300/001-002 | Avastin | Liechtenstein | 28.2.2010 |
| EU/1/04/300/001-002/IS | Avastin | Iceland | 11.1.2010 |
| EU/1/04/302/001/NO-004/NO | Prialt | Norway | 8.2.2010 |
| EU/1/04/302/001-004 | Prialt | Liechtenstein | 28.2.2010 |
| EU/1/04/302/001-004/IS | Prialt | Iceland | 17.3.2010 |
| EU/1/04/303/001/NO-003 | Orfadin | Norway | 3.2.2010 |
| EU/1/04/303/001-003 | Orfadin | Liechtenstein | 28.2.2010 |
| EU/1/04/303/001-003/IS | Orfadin | Iceland | 28.1.2010 |
| EU/1/04/304/001/NO-007/NO | Azilect | Norway | 10.2.2010 |
| EU/1/04/305/001/NO-002/NO | Truvada | Norway | 3.2.2010 |
| EU/1/04/305/001-002 | Truveda | Liechtenstein | 28.2.2010 |
| EU/1/04/305/001-002/IS | Truvada | Iceland | 28.1.2010 |
| EU/1/04/306/001 | Aloxi | Liechtenstein | 30.4.2010 |
| EU/1/04/306/001/IS | Aloxi | Iceland | 11.5.2010 |
| EU/1/04/306/01/NO | Aloxi | Norway | 23.4.2010 |
| EU/1/04/307/001/NO-013/NO | Zonegran | Norway | 5.2.2010 |
| EU/1/04/307/001-013 | Zonegran | Liechtenstein | 28.2.2010 |
| EU/1/04/307/001-013/IS | Zonegran | Iceland | 13.1.2010 |
| EU/1/05/308/001/NO-002/NO | Aclasta | Norway | 23.4.2010 |
| EU/1/05/308/001-002 | Aclasta | Liechtenstein | 30.4.2010 |
| EU/1/05/308/001-002/IS | Aclasta | Iceland | 30.4.2010 |
| EU/1/06/367/001-012 | Diacomit | Liechtenstein | 28.2.2010 |
| EU/1/07/423/001-003 | Vectibix | Liechtenstein | 30.4.2010 |
| EU/1/07/423/001-003/IS | Vectibix | Iceland | 7.4.2010 |
| EU/1/07/440/001-003/IS | Tyverb | Iceland | 30.6.2010 |
| EU/1/10/618/001/NO-004/NO | Prolia | Norway | 14.6.2010 |
| EU/1/99/122/001-002 | Thyrogen | Liechtenstein | 28.2.2010 |
| EU/1/99/122/001-002/IS | Thyrogen | Iceland | 19.2.2010 |
| EU/1/99/123/005/NO-013/NO | Renagel | Norway | 14.1.2010 |
| EU/1/99/123/005-013 | Renagel | Liechtenstein | 28.2.2010 |
| EU/1/99/123/005-013/IS | Renagel | Iceland | 5.1.2010 |
| EU/1/99/124/001/NO-002/NO | Tractocile | Norway | 27.1.2010 |
| EU/1/99/124/001-002 | Tractocile | Liechtenstein | 28.2.2010 |
| EU/1/99/124/001-002/IS | Tractocile | Iceland | 18.1.2010 |
| EU/1/99/126/001/NO-021/NO | Enbrel | Norway | 14.1.2010 |
| EU/1/99/127/011/NO-044/NO | IntronA | Norway | 21.4.2010 |
| EU/1/99/127/011-039 & 041-044/IS | IntronA | Iceland | 19.4.2010 |
| EU/1/99/127/011-044 | IntronA | Liechtenstein | 30.4.2010 |
| EU/2/00/018/001 | Incurin | Liechtenstein | 30.4.2010 |
| EU/2/00/018/001/IS | Incurin | Iceland | 21.4.2010 |
| EU/2/00/018/001/NO | Incurin | Norway | 10.5.2010 |
| EU/2/00/019/005/NO-007/NO | Purevax FeLV | Norway | 10.5.2010 |
| EU/2/00/019/005-007 | Purevax FeLV | Liechtenstein | 30.4.2010 |
| EU/2/00/019/005-007/IS | Purevax FeLV | Iceland | 10.5.2010 |
| EU/2/00/021/001-002 | Rabigen SAG2 | Liechtenstein | 30.4.2010 |
| EU/2/00/021/001-002/IS | Rabigen SAG2 | Iceland | 5.5.2010 |
| EU/2/00/022/001a-001b,
  EU/2/00/022/002a-002b,
  EU/2/00/022/003a-003b,
  EU/2/022/004a-004b,
  EU/2/00/022/005-017 | Ibaflin | Liechtenstein | 30.6.2010 |
| EU/2/00/022/003-004 a+b&007-008/IS | Ibaflin | Iceland | 22.6.2010 |
| EU/2/00/022/001-002 a+b&005-006/IS | Ibaflin | Iceland | 22.6.2010 |
| EU/2/00/22/009-017/IS | Ibaflin | Iceland | 22.6.2010 |
| EU/2/04/043/001/IS | Equilis StrepE | Iceland | 14.4.2010 |
| EU/2/04/047/001/NO-002/NO | Purevax RCPCh FeLV | Norway | 24.2.2010 |
| EU/2/04/047/001-002 | Purevax RCPCh FeLV | Liechtenstein | 28.2.2010 |
| EU/2/04/047/001-002/IS | Purevax RCPCh FeLV | Iceland | 15.1.2010 |
| EU/2/04/048/001-002 | Purevax RCP FeLV | Liechtenstein | 28.2.2010 |
| EU/2/04/048/001-002/IS | Purevax RCP FeLV | Iceland | 9.2.2010 |
| EU/2/04/049/001-002 | Purevax RCCh | Liechtenstein | 28.2.2010 |
| EU/2/04/049/001-002/IS | Purevax RCCh | Iceland | 9.2.2010 |
| EU/2/04/051/001-002 | Purevax RC | Liechtenstein | 28.2.2010 |
| EU/2/04/051/001-002/IS | Purevax RC | Iceland | 9.2.2010 |
| EU/2/04/052/001-002/IS | Purevax RCP | Iceland | 9.2.2010 |
| EU/2/04/50/001-002/IS | Purevax RCPCh | Iceland | 8.2.2010 |
| EU/2/05/053/001-003 | Naxcel | Liechtenstein | 30.6.2010 |
| EU/2/99/013/001/NO-002/NO | Halocur | Norway | 26.4.2010 |
| EU/2/99/013/001-002/IS | Halocur | Iceland | 15.3.2010 |
| EU/2/99/017/001/NO-006/NO | Ibraxion | Norway | 11.5.2010 |
| EU/2/99/017/001-006/IS | Ibraxion | Iceland | 25.5.2010 |

EU-Number

Product

Country

Date of authorisation

EU/1/00/129/001-003

Azopt

Liechtenstein

28.2.2010

EU/1/00/129/001-003/IS

Azopt

Iceland

16.3.2010

EU/1/00/130/001/NO-002/NO

Orgalutran

Norway

8.6.2010

EU/1/00/130/001-002

Orgalutran

Liechtenstein

30.6.2010

EU/1/00/130/001-002/IS

Orgalutran

Iceland

25.6.2010

EU/1/00/131/001/NO-005/NO

PegIntron

Norway

26.5.2010

EU/1/00/131/001-050

PegIntron

Liechtenstein

30.6.2010

EU/1/00/131/001-050/IS

PegIntron

Iceland

24.6.2010

EU/1/00/132/001/NO-050/NO

ViraferonPeg

Norway

26.5.2010

EU/1/00/132/001-050

ViraferonPeg

Liechtenstein

30.6.2010

EU/1/00/132/001-050/IS

ViraferonPeg

Iceland

25.6.2010

EU/1/00/133/001/NO-032/NO

Optisulin

Norway

25.5.2010

EU/1/00/133/001-032

Optisulin

Liechtenstein

30.6.2010

EU/1/00/133/001-032/IS

Optisulin

Iceland

25.6.2010

EU/1/00/134/001/NO-037/NO

Lantus

Norway

25.5.2010

EU/1/00/134/001-037

Lantus

Liechtenstein

30.6.2010

EU/1/00/134/001-037/IS

Lantus

Iceland

25.6.2010

EU/1/00/137/002/NO-018/NO

Avandia

Norway

7.6.2010

EU/1/00/137/002-012/IS

Avandia

Iceland

18.6.2010

EU/1/00/137/002-018

Avandia

Liechtenstein

30.6.2010

EU/1/00/140/001

Visudyne

Liechtenstein

30.6.2010

EU/1/00/140/001/IS

Visudyne

Iceland

23.6.2010

EU/1/04/272/001/NO-002/NO

PhotoBarr

Norway

17.2.2010

EU/1/04/294/001-028

Emselex

Liechtenstein

28.2.2010

EU/1/04/298/001/NO-003/NO

Kivexa

Norway

19.1.2010

EU/1/04/298/001-003

Kivexa

Liechtenstein

28.2.2010

EU/1/04/299/001/NO-003/NO

Fendrix

Norway

3.2.2010

EU/1/04/299/001-003

Fendrix

Liechtenstein

28.2.2010

EU/1/04/299/001-003/IS

Fendrix

Iceland

7.1.2010

EU/1/04/300/001/NO-002/NO

Avastin

Norway

26.1.2010

EU/1/04/300/001-002

Avastin

Liechtenstein

28.2.2010

EU/1/04/300/001-002/IS

Avastin

Iceland

11.1.2010

EU/1/04/302/001/NO-004/NO

Prialt

Norway

8.2.2010

EU/1/04/302/001-004

Prialt

Liechtenstein

28.2.2010

EU/1/04/302/001-004/IS

Prialt

Iceland

17.3.2010

EU/1/04/303/001/NO-003

Orfadin

Norway

3.2.2010

EU/1/04/303/001-003

Orfadin

Liechtenstein

28.2.2010

EU/1/04/303/001-003/IS

Orfadin

Iceland

28.1.2010

EU/1/04/304/001/NO-007/NO

Azilect

Norway

10.2.2010

EU/1/04/305/001/NO-002/NO

Truvada

Norway

3.2.2010

EU/1/04/305/001-002

Truveda

Liechtenstein

28.2.2010

EU/1/04/305/001-002/IS

Truvada

Iceland

28.1.2010

EU/1/04/306/001

Aloxi

Liechtenstein

30.4.2010

EU/1/04/306/001/IS

Aloxi

Iceland

11.5.2010

EU/1/04/306/01/NO

Aloxi

Norway

23.4.2010

EU/1/04/307/001/NO-013/NO

Zonegran

Norway

5.2.2010

EU/1/04/307/001-013

Zonegran

Liechtenstein

28.2.2010

EU/1/04/307/001-013/IS

Zonegran

Iceland

13.1.2010

EU/1/05/308/001/NO-002/NO

Aclasta

Norway

23.4.2010

EU/1/05/308/001-002

Aclasta

Liechtenstein

30.4.2010

EU/1/05/308/001-002/IS

Aclasta

Iceland

30.4.2010

EU/1/06/367/001-012

Diacomit

Liechtenstein

28.2.2010

EU/1/07/423/001-003

Vectibix

Liechtenstein

30.4.2010

EU/1/07/423/001-003/IS

Vectibix

Iceland

7.4.2010

EU/1/07/440/001-003/IS

Tyverb

Iceland

30.6.2010

EU/1/10/618/001/NO-004/NO

Prolia

Norway

14.6.2010

EU/1/99/122/001-002

Thyrogen

Liechtenstein

28.2.2010

EU/1/99/122/001-002/IS

Thyrogen

Iceland

19.2.2010

EU/1/99/123/005/NO-013/NO

Renagel

Norway

14.1.2010

EU/1/99/123/005-013

Renagel

Liechtenstein

28.2.2010

EU/1/99/123/005-013/IS

Renagel

Iceland

5.1.2010

EU/1/99/124/001/NO-002/NO

Tractocile

Norway

27.1.2010

EU/1/99/124/001-002

Tractocile

Liechtenstein

28.2.2010

EU/1/99/124/001-002/IS

Tractocile

Iceland

18.1.2010

EU/1/99/126/001/NO-021/NO

Enbrel

Norway

14.1.2010

EU/1/99/127/011/NO-044/NO

IntronA

Norway

21.4.2010

EU/1/99/127/011-039 & 041-044/IS

IntronA

Iceland

19.4.2010

EU/1/99/127/011-044

IntronA

Liechtenstein

30.4.2010

EU/2/00/018/001

Incurin

Liechtenstein

30.4.2010

EU/2/00/018/001/IS

Incurin

Iceland

21.4.2010

EU/2/00/018/001/NO

Incurin

Norway

10.5.2010

EU/2/00/019/005/NO-007/NO

Purevax FeLV

Norway

10.5.2010

EU/2/00/019/005-007

Purevax FeLV

Liechtenstein

30.4.2010

EU/2/00/019/005-007/IS

Purevax FeLV

Iceland

10.5.2010

EU/2/00/021/001-002

Rabigen SAG2

Liechtenstein

30.4.2010

EU/2/00/021/001-002/IS

Rabigen SAG2

Iceland

5.5.2010

EU/2/00/022/001a-001b,

EU/2/00/022/002a-002b,

EU/2/00/022/003a-003b,

EU/2/022/004a-004b,

EU/2/00/022/005-017

Ibaflin

Liechtenstein

30.6.2010

EU/2/00/022/003-004 a+b&007-008/IS

Ibaflin

Iceland

22.6.2010

EU/2/00/022/001-002 a+b&005-006/IS

Ibaflin

Iceland

22.6.2010

EU/2/00/22/009-017/IS

Ibaflin

Iceland

22.6.2010

EU/2/04/043/001/IS

Equilis StrepE

Iceland

14.4.2010

EU/2/04/047/001/NO-002/NO

Purevax RCPCh FeLV

Norway

24.2.2010

EU/2/04/047/001-002

Purevax RCPCh FeLV

Liechtenstein

28.2.2010

EU/2/04/047/001-002/IS

Purevax RCPCh FeLV

Iceland

15.1.2010

EU/2/04/048/001-002

Purevax RCP FeLV

Liechtenstein

28.2.2010

EU/2/04/048/001-002/IS

Purevax RCP FeLV

Iceland

9.2.2010

EU/2/04/049/001-002

Purevax RCCh

Liechtenstein

28.2.2010

EU/2/04/049/001-002/IS

Purevax RCCh

Iceland

9.2.2010

EU/2/04/051/001-002

Purevax RC

Liechtenstein

28.2.2010

EU/2/04/051/001-002/IS

Purevax RC

Iceland

9.2.2010

EU/2/04/052/001-002/IS

Purevax RCP

Iceland

9.2.2010

EU/2/04/50/001-002/IS

Purevax RCPCh

Iceland

8.2.2010

EU/2/05/053/001-003

Naxcel

Liechtenstein

30.6.2010

EU/2/99/013/001/NO-002/NO

Halocur

Norway

26.4.2010

EU/2/99/013/001-002/IS

Halocur

Iceland

15.3.2010

EU/2/99/017/001/NO-006/NO

Ibraxion

Norway

11.5.2010

EU/2/99/017/001-006/IS

Ibraxion

Iceland

25.5.2010

---

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2010:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/00/152/019-020 | Infanrix hexa | Liechtenstein | 30.6.2010 |
| EU/1/00/156/004 | Trizivir | Liechtenstein | 30.6.2010 |
| EU/1/01/172/007 | Kaletra | Liechtenstein | 28.2.2010 |
| EU/1/02/205/003/NO-004/NO | Lumigan | Norway | 12.3.2010 |
| EU/1/02/205/003-004 | Lumigan | Liechtenstein | 28.2.2010 |
| EU/1/02/205/003-004/IS | Lumigan | Iceland | 21.1.2010 |
| EU/1/04/278/010-011 | Levemir | Liechtenstein | 30.4.2010 |
| EU/1/04/306/002-003 | Aloxi | Liechtenstein | 30.6.2010 |
| EU/1/04/306/002-003/IS | Aloxi | Iceland | 11.5.2010 |
| EU/1/05/318/002 | Revatio | Liechtenstein | 28.2.2010 |
| EU/1/05/318/002/IS | Revatio | Iceland | 14.1.2010 |
| EU/1/05/318/002/NO | Revatio | Norway | 18.1.2010 |
| EU/1/05/329/006 | Kiovig | Liechtenstein | 30.6.2010 |
| EU/1/06/334/005 | Evoltra | Liechtenstein | 28.2.2010 |
| EU/1/06/360/013 | Champix | Liechtenstein | 28.2.2010 |
| EU/1/07/384/003/NO-004/NO | Docetaxel Winthrop | Norway | 1.2.2010 |
| EU/1/07/384/003-004 | Docetaxel Winthrop | Liechtenstein | 28.2.2010 |
| EU/1/07/384/005 | Docetaxel Winthrop | Liechtenstein | 30.6.2010 |
| EU/1/07/386/017-018 | Toviaz | Liechtenstein | 28.2.2010 |
| EU/1/07/400/022-024 | Mircera | Liechtenstein | 30.4.2010 |
| EU/1/07/405/021-040 | Rasilez | Liechtenstein | 28.2.2010 |
| EU/1/07/411/021-026/IS | Epoetin alfa Hexal | Iceland | 3.2.2010 |
| EU/1/07/412/021/NO-026/NO | Abseamed | Norway | 13.1.2010 |
| EU/1/07/412/021-026 | Abseamed | Liechtenstein | 28.2.2010 |
| EU/1/07/440/003 | Tyverb | Liechtenstein | 30.6.2010 |
| EU/1/08/444/009-012 | Ratiograstim | Liechtenstein | 28.2.2010 |
| EU/1/08/445/009-014 | Tevagrastim | Liechtenstein | 28.2.2010 |
| EU/1/08/450/009-010 | Biograstim | Liechtenstein | 28.2.2010 |
| EU/1/08/453/002/NO | Prepandrix | Norway | 9.2.2010 |
| EU/1/08/467/002 | Doribax | Liechtenstein | 30.4.2010 |
| EU/1/08/467/002/IS | Doribax | Iceland | 15.6.2010 |
| EU/1/08/494/003-004 | Stelara | Liechtenstein | 30.4.2010 |
| EU/1/08/497/005/NO-008/NO | Nplate | Norway | 2.2.2010 |
| EU/1/08/497/005-008 | Nplate | Liechtenstein | 28.2.2010 |
| EU/1/08/497/005-008/IS | Nplate | Iceland | 22.1.2010 |
| EU/1/09/508/010 | Synflorix | Liechtenstein | 28.2.2010 |
| EU/1/09/525/047-050 | Nimvastid | Liechtenstein | 30.4.2010 |
| EU/1/09/526/002 | Iressa | Liechtenstein | 28.2.2010 |
| EU/1/09/528/002 | Nymusa | Liechtenstein | 30.6.2010 |
| EU/1/09/538/007-008 | Afinitor | Liechtenstein | 30.4.2010 |
| EU/1/09/540/010-016 | Clopidogrel Teva | Liechtenstein | 30.4.2010 |
| EU/1/09/556/010-011 | Clopidogrel Krka | Liechtenstein | 30.4.2010 |
| EU/1/09/557/010 | Clopidogrel Qualimed | Liechtenstein | 30.4.2010 |
| EU/1/09/559/010-016 | Clopidogrel Mylan | Liechtenstein | 30.4.2010 |
| EU/1/95/002/003/NO-004/NO | Taxotere | Norway | 25.1.2010 |
| EU/1/95/002/003-004 | Taxotere | Liechtenstein | 28.2.2010 |
| EU/1/95/002/005 | Taxotere | Liechtenstein | 30.6.2010 |
| EU/1/96/016/005/NO-006/NO | Norvir | Norway | 9.2.2010 |
| EU/1/96/016/005-006 | Norvir | Liechtenstein | 28.2.2010 |
| EU/1/96/016/005-006/IS | Norvir | Iceland | 12.2.2010 |
| EU/1/97/050/028-033 | Sifrol | Liechtenstein | 30.6.2010 |
| EU/1/98/069/012 | Plavix | Liechtenstein | 30.4.2010 |
| EU/1/98/070/012 | Iscover | Liechtenstein | 30.4.2010 |
| EU/1/98/080/002 | Aldara | Liechtenstein | 30.4.2010 |
| EU/1/98/096/024-025 | Temodal | Liechtenstein | 28.2.2010 |
| EU/1/97/051/028-033 | Mirapexin | Liechtenstein | 30.6.2010 |
| EU/2/02/032/002 | Vaxxitek HVT+IBD | Liechtenstein | 30.6.2010 |
| EU/2/04/044/011/NO-013/NO | Aivlosin | Norway | 29.4.2010 |
| EU/2/04/044/011-013 | Aivlosin | Liechtenstein | 28.2.2010 |
| EU/2/04/044/011-013/IS | Aivlosin | Iceland | 7.1.2010 |
| EU/2/06/070/004/IS | Meloxidyl | Iceland | 25.1.2010 |
| EU/2/06/070/005-007 | Meloxidyl | Liechtenstein | 30.4.2010 |
| EU/2/08/083/002-003 | Equioxx | Liechtenstein | 28.2.2010 |
| EU/2/08/083/002-003/IS | Equioxx | Iceland | 11.1.2010 |
| EU/2/08/089/021 | Onsior | Liechtenstein | 28.2.2010 |
| EU/2/08/090/009 | Loxicom | Liechtenstein | 30.4.2010 |
| EU/2/97/004/035-038 | Metacam | Liechtenstein | 28.2.2010 |

EU-Number

Product

Country

Date of authorisation

EU/1/00/152/019-020

Infanrix hexa

Liechtenstein

30.6.2010

EU/1/00/156/004

Trizivir

Liechtenstein

30.6.2010

EU/1/01/172/007

Kaletra

Liechtenstein

28.2.2010

EU/1/02/205/003/NO-004/NO

Lumigan

Norway

12.3.2010

EU/1/02/205/003-004

Lumigan

Liechtenstein

28.2.2010

EU/1/02/205/003-004/IS

Lumigan

Iceland

21.1.2010

EU/1/04/278/010-011

Levemir

Liechtenstein

30.4.2010

EU/1/04/306/002-003

Aloxi

Liechtenstein

30.6.2010

EU/1/04/306/002-003/IS

Aloxi

Iceland

11.5.2010

EU/1/05/318/002

Revatio

Liechtenstein

28.2.2010

EU/1/05/318/002/IS

Revatio

Iceland

14.1.2010

EU/1/05/318/002/NO

Revatio

Norway

18.1.2010

EU/1/05/329/006

Kiovig

Liechtenstein

30.6.2010

EU/1/06/334/005

Evoltra

Liechtenstein

28.2.2010

EU/1/06/360/013

Champix

Liechtenstein

28.2.2010

EU/1/07/384/003/NO-004/NO

Docetaxel Winthrop

Norway

1.2.2010

EU/1/07/384/003-004

Docetaxel Winthrop

Liechtenstein

28.2.2010

EU/1/07/384/005

Docetaxel Winthrop

Liechtenstein

30.6.2010

EU/1/07/386/017-018

Toviaz

Liechtenstein

28.2.2010

EU/1/07/400/022-024

Mircera

Liechtenstein

30.4.2010

EU/1/07/405/021-040

Rasilez

Liechtenstein

28.2.2010

EU/1/07/411/021-026/IS

Epoetin alfa Hexal

Iceland

3.2.2010

EU/1/07/412/021/NO-026/NO

Abseamed

Norway

13.1.2010

EU/1/07/412/021-026

Abseamed

Liechtenstein

28.2.2010

EU/1/07/440/003

Tyverb

Liechtenstein

30.6.2010

EU/1/08/444/009-012

Ratiograstim

Liechtenstein

28.2.2010

EU/1/08/445/009-014

Tevagrastim

Liechtenstein

28.2.2010

EU/1/08/450/009-010

Biograstim

Liechtenstein

28.2.2010

EU/1/08/453/002/NO

Prepandrix

Norway

9.2.2010

EU/1/08/467/002

Doribax

Liechtenstein

30.4.2010

EU/1/08/467/002/IS

Doribax

Iceland

15.6.2010

EU/1/08/494/003-004

Stelara

Liechtenstein

30.4.2010

EU/1/08/497/005/NO-008/NO

Nplate

Norway

2.2.2010

EU/1/08/497/005-008

Nplate

Liechtenstein

28.2.2010

EU/1/08/497/005-008/IS

Nplate

Iceland

22.1.2010

EU/1/09/508/010

Synflorix

Liechtenstein

28.2.2010

EU/1/09/525/047-050

Nimvastid

Liechtenstein

30.4.2010

EU/1/09/526/002

Iressa

Liechtenstein

28.2.2010

EU/1/09/528/002

Nymusa

Liechtenstein

30.6.2010

EU/1/09/538/007-008

Afinitor

Liechtenstein

30.4.2010

EU/1/09/540/010-016

Clopidogrel Teva

Liechtenstein

30.4.2010

EU/1/09/556/010-011

Clopidogrel Krka

Liechtenstein

30.4.2010

EU/1/09/557/010

Clopidogrel Qualimed

Liechtenstein

30.4.2010

EU/1/09/559/010-016

Clopidogrel Mylan

Liechtenstein

30.4.2010

EU/1/95/002/003/NO-004/NO

Taxotere

Norway

25.1.2010

EU/1/95/002/003-004

Taxotere

Liechtenstein

28.2.2010

EU/1/95/002/005

Taxotere

Liechtenstein

30.6.2010

EU/1/96/016/005/NO-006/NO

Norvir

Norway

9.2.2010

EU/1/96/016/005-006

Norvir

Liechtenstein

28.2.2010

EU/1/96/016/005-006/IS

Norvir

Iceland

12.2.2010

EU/1/97/050/028-033

Sifrol

Liechtenstein

30.6.2010

EU/1/98/069/012

Plavix

Liechtenstein

30.4.2010

EU/1/98/070/012

Iscover

Liechtenstein

30.4.2010

EU/1/98/080/002

Aldara

Liechtenstein

30.4.2010

EU/1/98/096/024-025

Temodal

Liechtenstein

28.2.2010

EU/1/97/051/028-033

Mirapexin

Liechtenstein

30.6.2010

EU/2/02/032/002

Vaxxitek HVT+IBD

Liechtenstein

30.6.2010

EU/2/04/044/011/NO-013/NO

Aivlosin

Norway

29.4.2010

EU/2/04/044/011-013

Aivlosin

Liechtenstein

28.2.2010

EU/2/04/044/011-013/IS

Aivlosin

Iceland

7.1.2010

EU/2/06/070/004/IS

Meloxidyl

Iceland

25.1.2010

EU/2/06/070/005-007

Meloxidyl

Liechtenstein

30.4.2010

EU/2/08/083/002-003

Equioxx

Liechtenstein

28.2.2010

EU/2/08/083/002-003/IS

Equioxx

Iceland

11.1.2010

EU/2/08/089/021

Onsior

Liechtenstein

28.2.2010

EU/2/08/090/009

Loxicom

Liechtenstein

30.4.2010

EU/2/97/004/035-038

Metacam

Liechtenstein

28.2.2010

---

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2010:

| EU-Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/00/148/001-004 | Agenerase | Liechtenstein | 30.6.2010 |
| EU/1/00/148/001-004/IS | Agenerase | Iceland | 29.6.2010 |
| EU/1/06/375/001-033 | Irbesartan BMS | Liechtenstein | 28.2.2010 |
| EU/1/08/471/001-012/IS | Duloxetine
  Boehringer
  Ingelheim | Iceland | 25.6.2010 |
| EU/1/08/471/003-005, 011-012 | Duloxetine
  Boehringer
  Ingelheim | Liechtenstein | 30.6.2010 |
| EU/1/99/113/001-004 | Paxene | Liechtenstein | 28.2.2010 |

EU-Number

Product

Country

Date of withdrawal

EU/1/00/148/001-004

Agenerase

Liechtenstein

30.6.2010

EU/1/00/148/001-004/IS

Agenerase

Iceland

29.6.2010

EU/1/06/375/001-033

Irbesartan BMS

Liechtenstein

28.2.2010

EU/1/08/471/001-012/IS

Duloxetine

Boehringer

Ingelheim

Iceland

25.6.2010

EU/1/08/471/003-005, 011-012

Duloxetine

Boehringer

Ingelheim

Liechtenstein

30.6.2010

EU/1/99/113/001-004

Paxene

Liechtenstein

28.2.2010

---

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2010:

| EU-Number | Product | Country | Date of suspension |
| --- | --- | --- | --- |
| EU/1/09/532/001-007 | Clopidogrel Acino | Liechtenstein | 30.4.2010 |
| EU/1/09/532/001-007/IS | Clopidogrel Acino | Iceland | 30.4.2010 |
| EU/1/09/534/001-007 | Clopidogrel Hexal | Liechtenstein | 30.4.2010 |
| EU/1/09/534/001-007 | Clopidogrel Sandoz | Liechtenstein | 30.4.2010 |
| EU/1/09/534/001-007/IS | Clopidogrel Hexal | Iceland | 30.4.2010 |
| EU/1/09/541/001-007/IS | Clopidogrel ratiopharm GmbH | Iceland | 30.4.2010 |
| EU/1/09/541/001-008 | Clopidogrel ratiopharm GmbH | Liechtenstein | 30.4.2010 |
| EU/1/09/542/001-007 | Clopidogrel 1A Pharma | Liechtenstein | 30.4.2010 |
| EU/1/09/542/001-007/IS | Clopidogrel 1A Pharma | Iceland | 30.4.2010 |
| EU/1/09/547/001-007/IS | Clopidogrel Sandoz | Iceland | 30.4.2010 |
| EU/1/09/548/001-007 | Clopidogrel Acino Pharma GmbH | Liechtenstein | 30.4.2010 |
| EU/1/09/548/001-007/IS | Clopidogrel Acino Pharma GmbH | Iceland | 30.4.2010 |
| EU/1/09/554/001-007/IS | Clopidogrel ratiopharm | Iceland | 30.4.2010 |
| EU/1/09/554/001-008 | Clopidogrel ratiopharm | Liechtenstein | 30.4.2010 |

EU-Number

Product

Country

Date of suspension

EU/1/09/532/001-007

Clopidogrel Acino

Liechtenstein

30.4.2010

EU/1/09/532/001-007/IS

Clopidogrel Acino

Iceland

30.4.2010

EU/1/09/534/001-007

Clopidogrel Hexal

Liechtenstein

30.4.2010

EU/1/09/534/001-007

Clopidogrel Sandoz

Liechtenstein

30.4.2010

EU/1/09/534/001-007/IS

Clopidogrel Hexal

Iceland

30.4.2010

EU/1/09/541/001-007/IS

Clopidogrel ratiopharm GmbH

Iceland

30.4.2010

EU/1/09/541/001-008

Clopidogrel ratiopharm GmbH

Liechtenstein

30.4.2010

EU/1/09/542/001-007

Clopidogrel 1A Pharma

Liechtenstein

30.4.2010

EU/1/09/542/001-007/IS

Clopidogrel 1A Pharma

Iceland

30.4.2010

EU/1/09/547/001-007/IS

Clopidogrel Sandoz

Iceland

30.4.2010

EU/1/09/548/001-007

Clopidogrel Acino Pharma GmbH

Liechtenstein

30.4.2010

EU/1/09/548/001-007/IS

Clopidogrel Acino Pharma GmbH

Iceland

30.4.2010

EU/1/09/554/001-007/IS

Clopidogrel ratiopharm

Iceland

30.4.2010

EU/1/09/554/001-008

Clopidogrel ratiopharm

Liechtenstein

30.4.2010

---

V Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

| 13.1.2011 | EN | Official Journal of the European Union | C 8/20 |
| --- | --- | --- | --- |

13.1.2011

EN

Official Journal of the European Union

C 8/20

---

Initiation of proceedings

(Case COMP/M.5907 — Votorantim/Fischer/JV)

(Text with EEA relevance)

2011/C 8/08

On 7 January 2011, the Commission decided to initiate proceedings in the above mentioned case after finding that the notified concentration raises serious doubts as to its compatibility with the common market. The initiation of proceedings opens a second phase investigation with regard to the notified concentration, and is without prejudice to the final decision on the case. The decision is based on Article 6(1)(c) of Council Regulation (EC) No 139/2004.

The Commission invites interested third parties to submit their observations on the proposed concentration to the Commission.

In order to be fully taken into account in the procedure, observations should reach the Commission not later than 15 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301 / 2967244) or by post, under reference COMP/M.5907 — Votorantim/Fischer/JV, to the following address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---